帕洛诺司琼、阿瑞匹坦、地塞米松联合预防含卡铂方案化疗所致呕吐的疗效与安全性

摘要

目的:观察帕洛诺司琼、阿瑞匹坦、地塞米松三药联合对含卡铂方案化疗的止吐效果与安全性.方法:以2015年1月至2017年1月期间在我院内科住院的96例符合条件的初治晚期非小细胞肺癌患者为研究对象,观察三药联合对含卡铂的双药化疗所导致的恶心、呕吐(chemotherapy-induced nausea and vomiting, CINV)的效果.化疗前预防性应用帕洛诺司琼0.75 mg d1,地塞米松10 mg d1,阿瑞匹坦125 mg d1、80 mg d2,3.记录化疗后急性呕吐(0~24小时)、延迟性呕吐(24~120小时)和总呕吐的发生率.记录患者治疗过程中出现的所有不良反应.结果:急性呕吐发生率为0%,延迟性呕吐发生率为8.3%,总呕吐发生率为8.3%.最常见的不良反应为轻中度便秘,未发现Ⅳ度不良反应.结论:帕洛诺司琼、阿瑞匹坦、地塞米松三药联合对含卡铂方案CINV疗效满意,不良反应轻微,耐受良好.%Objective:To test the antiemetic efficacy and safety of triple antiemetic therapy comprising palonose-tron,aprepitant and dexamethasone for carboplatin -based chemotherapy. Methods:Chemotherapy -naive patients with advanced non-small cell lung cancer scheduled for a first course of a carboplatin-containing double drugs regi-men formed the study cohort.Patients were pretreated with antiemetic therapy comprising palonosetron(0.75 mg d1) and dexamethasone(10 mg d1),and aprepitant(125 mg d1,80 mg d2,3).The incidence of acute(0~24 h),delayed (24~120 h)and overall vomiting after chemotherapy were noted.The overall adverse events were noted.Results:The rate of vomiting during the acute phase,delayed phase,and overall were 0%,8.3% and 8.3%.The most com-mon adverse event was mild constipation.Severe adverse events related to antiemetic treatment were not observed. Conclusion:Triple antiemetic therapy comprising palonosetron,dexamethasone and aprepitant shows excellent effects in the prevention of vomiting in patients receiving a carboplatin-containing regimen.The adverse events were mild and well tolerated.